Novo Nordisk expands portfolio with new universal needle

PLAINSBORO, N.J. — Novo Nordisk announced the launch of NovoFine Plus in the United States. NovoFine Plus is a universal needle that works with all currently available insulin as well as some GLP-1 receptor agonist pens, the company said. 

 

The needle measures 32 gauge and 4 mm long, making it one of the shortest, thinnest diabetes pen needles on the market today, according to Novo Nordisk. The new needle incorporates SuperFlow technology, which enhances flow rate and lessens the dosage force when making an injection. 

 

"Novo Nordisk launched the world's first pen needle in 1985, and since then has strived to improve the injection experience for patients by developing smaller and thinner needles," said Camille Lee, senior vice president, diabetes marketing. "At the width of two human hairs, NovoFine Plus is now our thinnest needle, and it features many improvements that are designed to cause less pain upon injection."

 

 

NovoFine Plus will accompany Novo Nordisk's portfolio of pen needles, including NovoTwist 32G tip, NovoFine 32G tip and NovoFine Autocover 30G.